Sanofi has officially completed its acquisition of Vigil Neuroscience, Inc., further enhancing its early-stage neurology portfolio. The acquisition brings in VG-3927, a first-in-class, oral small-molecule TREM2 agonist, which is set to enter a Phase 2 clinical trial for the treatment of Alzheimer’s disease. Additionally, Vigil’s preclinical assets will support Sanofi’s broader research efforts in neurodegenerative diseases.
This acquisition follows Sanofi’s $40 million strategic investment in June 2024, which granted Sanofi the exclusive right of first negotiation for the development and commercialization of VG-3927.
Sanofi acquired all outstanding shares of Vigil for $8 per share in cash, valuing the deal at approximately $470 million on a fully diluted basis.
Shareholders of Vigil will also receive a non-transferable Contingent Value Right (CVR) of $2 per share, payable upon the first commercial sale of VG-3927.
VGL101, Vigil’s second clinical-stage asset, was not included in the transaction.
Sanofi confirmed that this acquisition will not impact its financial guidance for 2025, as previously stated.